A Nutrition Air Pocket Sparks a 10% Drop; the EPS Algorithm, a Diagnostics Inflection, and Exact Sciences Are Intact — Upgrading to Outperform

Results vs. Consensus

Q4 2025 Scorecard

Year-Over-Year Comparison

Full-Year 2025 Summary

Quality of Result

Revenue: The 2.9% top-line miss is real and is overwhelmingly Nutrition, which fell 9.1% organically on lower volumes plus the strategic price resets management initiated in Q4. Strip Nutrition out and the rest of the company grew roughly in line with its algorithm, Medical Devices +10.5%, EPD +7%, Core Lab Diagnostics accelerating. Full-year organic growth ex-COVID still landed at ~7.5%, on the algorithm. The miss is a Q4 air pocket concentrated in one segment, not a broad demand failure.

Margins: The standout. Adjusted operating margin expanded 150bp year-over-year to 25.8%, and adjusted gross margin rose 20bp to 57.1% despite the full tariff load, directly answering the gross-margin question we flagged as the gating risk in the Q3 recap. Full-year operating-margin expansion of ~110bp confirms the "double-digit EPS with margin expansion" pillar that looked at-risk a quarter ago is intact. The CFO guided to a continued 50–70bp of annual operating-margin improvement.

EPS: The $1.50 met consensus and grew 12%, and full-year EPS of $5.15 hit the original double-digit-growth target set a year earlier, through ~$1B of diagnostics headwind, a new tariff regime, and a Q4 nutrition collapse. That is the durability case in one data point: the diversified model absorbed a segment falling 9% and still delivered double-digit earnings growth.

Segment Performance

Nutrition, The Air Pocket and the Reset

Nutrition fell 9.1% organically to $1.94B, the worst result in the segment in years and the proximate cause of the revenue miss. Management was unusually candid about the mechanism: Nutrition is a healthcare-branded portfolio with a consumer-packaged-goods (CPG) dynamic underneath, and the post-pandemic surge in commodity/manufacturing costs (2022–2024) was offset with price increases that protected profitability but, in an increasingly price-sensitive consumer environment, suppressed volume. The volume pressure accelerated through Q4. Layered on top is a known U.S. Pediatric issue: the WIC-contract loss and competitive share give-back from the post-2022-disruption recovery.

Rather than ride the spiral another two-to-three quarters, management chose to act in Q4: price-and-promotion resets (tested pre-Thanksgiving in the U.S. and internationally, with early signs "encouraging"), a reallocation of the segment's ~2% R&D budget toward new-product development, and a pipeline of 8-plus launches over the next twelve months. The trade-off is explicit, Nutrition will be challenged in H1 2026 and return to growth in H2.

"Higher manufacturing costs led to higher prices, which in turn are suppressing demand as consumers become increasingly more price-sensitive… This path is not sustainable long-term, so we began to make changes in the fourth quarter… we'll have a couple of quarters where growth in nutrition is going to be challenged. And then in the second half, we'll return to positive growth." — Robert Ford, Chairman & CEO

Assessment: This is a genuine new negative and the reason the stock fell, but it is a fixable, self-inflicted reset on a ~14%-of-revenue segment, not a demand collapse in the device-and-diagnostics core. Management is rebasing price to reignite volume, holding the profitability profile roughly flat to 2025, and has a six-month runway with new-product support. We treat it as a transitory drag with a visible recovery, and note management chose short-term pain (a 10% stock drop) over a slow-motion structural decline. That is the right call; the market is pricing the pain and discounting the fix.

Medical Devices, Still the Engine, Catalysts Landing

Medical Devices grew 10.5% organically, a modest deceleration off tough comps but still the engine, and the quarter that delivered the device pipeline's most important regulatory milestones. The FDA approved the Volt PFA catheter in December, Abbott's first U.S. pulsed-field-ablation product, and the Tactiflex Duo (dual RF/PFA energy) won CE Mark. Combined with Abbott's installed mapping base and its Amulet LAA device, this completes the full EP toolbox Ford has been building toward for three years. Diabetes Care CGM grew 12% in Q4 (decelerating off a high base) but still added more than $1B for the third consecutive year, with 2025 CGM sales above $7.5B.

"I don't think that there is a company right now that's better positioned in terms of completeness of the [EP] portfolio than what we have… we've got both RF and PFA products… and on top of that, we've got an LAA device, which is becoming pretty clear that if you want to be a leader in this space, you can't just look at having a PFA catheter." — Robert Ford, Chairman & CEO

Assessment: The device thesis strengthened on substance even as the growth rate cooled on comps. The U.S. Volt approval is the catalyst the EP bull case needed, and management expects EP to grow at least in line with a mid-to-high-teens market in 2026. The CGM deceleration to low-teens is a percentage-of-a-large-base story, not a demand crack, $1B of annual growth four years running, with the dual glucose-ketone sensor (FDA-filed) and a potential CMS non-insulin reimbursement as 2026 upside. The engine is intact.

Diagnostics, The Inflection Confirmed

Core Lab Diagnostics grew 3.5% in Q4, a third consecutive quarter of accelerating growth, with full-year ex-China Core Lab at +7% on durable U.S./Europe/LatAm demand and Alinity share capture. Point of Care grew 7% on the high-sensitivity troponin and concussion tests. Most important is the 2026 setup management laid out: the ~$1B of 2025 headwind (COVID stepping from ~$750M down to ~$250M, plus China VBP) largely laps, the vast majority of Abbott's China diagnostics sales already cleared VBP in 2025 (so remaining VBP waves hit small residual share), and the ex-China share-gain momentum continues. Diagnostics swings from 2025's drag to a 2026 accelerator.

"You've got this whole lapping of our diagnostic business. And as long as we keep on doing what we're doing in the United States, Europe, Latin America, and other parts of Asia… you're going to see a nice acceleration in our diagnostic business." — Robert Ford, Chairman & CEO

Assessment: This is the cleanest confirmation of the inflection we flagged as "forming" in Q3. The combination of a lapping comp, a near-complete China VBP reset, and accelerating ex-China share gains turns Diagnostics into a 2026 growth contributor. With Exact Sciences inbound on top, the diagnostics franchise that dragged all of 2025 becomes a multi-year growth story. Bear-1 is effectively resolving.

Established Pharmaceuticals (EPD), Five Straight Years

EPD grew 7% in Q4 and delivered its fifth consecutive year of 7%-plus sales growth, with double-digit growth in India and several Latin American and Middle Eastern markets, and the emerging-market biosimilar launch sequence underway.

Assessment: EPD remains the quietly excellent, demographics-driven compounder, now with a biosimilar growth layer building. A durable mid-to-high-single-digit support to the company algorithm and a 2026 sustaining contributor.

Key Topics & Management Commentary

Overall Management Tone: Direct and front-footed about the nutrition problem, and confident everywhere else. Where prior calls defended the diagnostics headwind, this call essentially declared it over and pivoted to a 2026 acceleration story. Management owned the nutrition stumble without hedging, framed it as a deliberate decision to take short-term pain for long-term health, and spent most of the call on the breadth of growth and pipeline catalysts underneath. The posture on the 10% stock reaction was implicit but clear: the franchise is intact, the algorithm delivered, and one fixable segment does not change the multi-year story.

1. The 2026 Guide: A Half-Point Lower, and Why

Abbott guided 2026 organic sales growth to 6.5–7.5% (7% midpoint) and adjusted EPS to $5.55–$5.80 (10% growth at the midpoint), with Q1 EPS of $1.12–$1.18. Ford was direct that the top-line midpoint is a half-point below the 7.5% consensus and that the entire delta is the near-term nutrition reset, "other than that, nothing's really changed." The EPS guide is in line with consensus and absorbs the ~$0.20 Exact Sciences dilution.

"Today, we guided the midpoint at 7% on the top line, 10% on the bottom… the half-point change on the top line is really the change in the near-term outlook of our nutrition business… A significant majority of the company is either maintaining high-single-digit growth or low-teens growth or accelerating versus 2025." — Robert Ford, Chairman & CEO

Assessment: The half-point haircut is entirely nutrition, and a 7% organic midpoint with 10% EPS growth is still squarely the Abbott algorithm. Critically, the EPS guide absorbs ~$0.20 of Exact Sciences dilution, meaning the underlying, ex-deal earnings algorithm is closer to low-double-digit. The market read "guide cut"; the more accurate read is "one segment trimmed, everything else intact, and a strategic dilution masking the underlying EPS power."

2. Exact Sciences: A New Cancer-Diagnostics Vertical

Abbott's announced acquisition of Exact Sciences adds a ~$3B-plus business growing ~15% in the fast-growing cancer-diagnostics market, Cologuard (colorectal screening) plus a multi-cancer-early-detection (MCED) pipeline. Management confirmed the deal is on track (regulatory clearances submitted, shareholder vote February 20), with no change to timing or the ~$0.20 2026 EPS dilution, and post-close gross-debt/EBITDA around 2.7x (ample capacity preserved). Ford was notably bullish on the MCED optionality, comparing a future routine cancer-screening test to an annual lipid or cardiometabolic panel.

"This is going to be another great opportunity for us… greater reimbursement of this type of test will really make this a very, very large segment… I just envision this being that type of test [an annual screening panel after a certain age]." — Robert Ford, Chairman & CEO

Assessment: Exact Sciences is a strategically coherent extension of Abbott's diagnostics leadership into oncology, adds a 15%-growing revenue vertical, and carries real MCED optionality that the ~$0.20 near-term dilution understates. It is precisely the kind of returns-focused, growth-additive deal management signaled for four quarters. The near-term dilution is the cost; the multi-year growth vertical is the prize. The market is pricing the dilution and ignoring the option value.

3. Nutrition: Owning the Stumble, Pricing the Fix

The most-discussed topic of the call. Ford diagnosed Nutrition as a CPG-style price/volume problem (cost-driven price increases that protected profitability but suppressed volume) and described the Q4 corrective actions (price-and-promotion resets tested pre-Thanksgiving, R&D reallocation, 8-plus launches). He expressed confidence the early signs are encouraging and that the segment returns to growth in H2 2026, holding the profitability profile roughly flat to 2025.

"We did some pricing work just before Thanksgiving… we got the results back on the U.S. side pretty quickly… based on what we have, I think we've kind of called it right. But… we've got to keep monitoring it." — Robert Ford, Chairman & CEO

Assessment: Management's diagnosis is credible and the corrective playbook is the right one, rebase price to reignite volume rather than defend a margin-protecting price that is killing the top line. The "we called it right" confidence is appropriately hedged with "keep monitoring." The key risk is execution: if the price resets do not restore volume by H2, the drag extends. We size this as a transitory two-to-three-quarter reset with a visible recovery path, and the single most important thing to verify on the Q1 and Q2 calls.

4. Electrophysiology: The U.S. PFA Toolbox Is Complete

The December U.S. FDA approval of the Volt PFA catheter and the Tactiflex Duo CE Mark complete the EP strategy management presented to its board three years ago. Ford emphasized that Abbott sustained double-digit EP growth in 2024–2025 without a PFA catheter, and now layers PFA onto a large installed mapping base. European Volt feedback (mapping-integrated visualization, conscious-sedation capability) has carried into the U.S. limited market release. With RF, PFA, and LAA (Amulet) products, Ford argues no competitor is better positioned on portfolio completeness, and expects EP to grow at least in line with a mid-to-high-teens market in 2026.

Assessment: This is the device catalyst the bull case needed and a direct refutation of the multi-year "Abbott is late to PFA" bear narrative. Sustaining double-digit EP growth without PFA, then adding the full PFA toolbox into an installed mapping base, is the strongest possible setup. A clear 2026 acceleration driver that the 10% reaction entirely overlooked.

5. CGM: Decelerating Percentages, Compounding Dollars

Asked about the "market is slowing" debate, Ford pushed back hard: CGM grew more than $1B for the fourth consecutive year (2025 sales >$7.5B), and low-teens percentage growth on a $7.5B base is not slowing in any way that matters. He sees continued penetration runway across intensive-insulin (only ~50% penetrated internationally), basal, and non-insulin segments, plus two specific expansion vectors: the dual glucose-ketone sensor (targeting the underpenetrated pump segment and a large SGLT2 population where only ~1 of ~6 million U.S. users currently uses CGM) and a potential CMS non-insulin reimbursement decision (not in the guide, pure upside).

"I don't consider growing a billion dollars every single year and doing it four years in a row to be slowing down… we're far away from being in the seventh inning on this one." — Robert Ford, Chairman & CEO

Assessment: The CGM deceleration is a law-of-large-numbers optic, not a demand problem, and the ketone-sensor plus SGLT2 market-expansion angle is a credible re-acceleration vector. CMS non-insulin coverage is genuine un-modeled upside. The crown jewel is maturing into a steadier compounder, not breaking. We keep the Libre pillar intact with a watch on whether the dual-analyte sensor re-accelerates growth in 2026–2027.

6. Margin Expansion Through Tariffs: Question Answered

The gross-margin risk we flagged in Q3 was answered emphatically: Q4 adjusted gross margin rose 20bp year-over-year to 57.1% despite the full tariff load, and operating margin expanded 150bp to 25.8% on SG&A leverage. The CFO committed to a continued 50–70bp of annual operating-margin improvement in 2026, delivered through both gross-margin expansion and P&L leverage, as the structural basis for the double-digit-EPS guide.

"We continue to look at a 50 to 70 basis point improvement in operating margins every year, and that's what we've got built into this… through both gross margin expansion… and leverage in the P&L." — Philip Boudreau, CFO

Assessment: This restores the margin-expansion pillar we marked at-risk last quarter. Abbott's gross-margin-improvement machinery offset the full tariff effect in the same quarter the tariffs fully landed, the best possible answer to the Q3 worry. The 50–70bp annual operating-margin algorithm is intact and underpins the double-digit EPS guide.

7. AVEIR / Rhythm Management: Early Innings of a Standard-of-Care Shift

Rhythm Management grew 12% in Q4 (FY +10%, third straight year outgrowing the market). Ford sized the global low-voltage pacing market at ~$5B with AVEIR at ~10% penetration ("early innings") and U.S. single-chamber (15% of the total market) about 50% penetrated. He framed leadless, lead-free, communicating, transfemorally-implanted pacing as the next CRM standard of care, supported by a continued new-product cadence.

Assessment: AVEIR remains the model example of Abbott's reposition-the-laggard playbook, with years of penetration runway (10% of a $5B market). The "foundational segments generating impressive returns" framing (CRM and Vascular both repositioned to durable growth) is the underappreciated mechanism that lets a 48%-of-revenue device segment compound at double digits.

8. Capital Allocation: Dividend Up, Integration First

Management raised the dividend again for 2026 (announced December), and Ford framed near-term capital allocation around closing and integrating Exact Sciences, with post-close gross-debt/EBITDA ~2.7x leaving ample capacity for future tuck-ins. On the spin-off-vs-M&A question circulating in MedTech, he signaled no appetite for structural separation and a continued returns-focused, balanced approach.

Assessment: Disciplined and shareholder-friendly, a growing dividend, a strategic acquisition that adds a growth vertical, and preserved balance-sheet capacity. Integration focus in 2026 is the right priority; the firepower for further tuck-ins remains.

9. The Durability Proof Point: Double-Digit EPS Through Adversity

The framing Ford returned to repeatedly: 2025 delivered the original double-digit-EPS target despite ~$1B of diagnostics headwind, a new tariff regime, China challenges, and a Q4 nutrition collapse. The diversified model absorbed a segment falling 9% and still grew earnings 12% in the quarter and 10% for the year.

Assessment: This is the core of the resilience thesis, and 2025 is its proof. A portfolio that can lose a leg (nutrition) and a tailwind (diagnostics) in the same year and still hit double-digit EPS with margin expansion is exactly the through-cycle compounder the premium multiple is meant to reward. The market's 10% reaction implicitly forgot this; we are upgrading because the year demonstrated it.

Guidance & Outlook

The 2026 guide is the crux of the sell-off and, in our read, the crux of the opportunity. The headline negatives, a 7% organic midpoint (half a point below the 7.5% Street) and a Q1 EPS guide ($1.12–$1.18) below the ~$1.20 consensus, are both nutrition-and-timing artifacts. The half-point top-line haircut is entirely the near-term nutrition reset; the soft Q1 reflects the nutrition trough plus the front-loaded FX/seasonal cadence (FX is a ~3% Q1 tailwind but the nutrition drag is heaviest early). The EPS guide of $5.55–$5.80 is in line with consensus and absorbs ~$0.20 of Exact Sciences dilution.

The cadence is back-half-weighted by design: management explicitly guided to an accelerating year, nutrition challenged in H1 and recovering in H2, diagnostics accelerating as the 2025 headwinds lap, the device pipeline (Volt U.S., dual-analyte sensor, coronary IVL) contributing, and Exact Sciences layering on. The shape of 2026 is a soft Q1 building to a stronger exit rate.

Underlying EPS power is understated by the headline: a 10% EPS guide that absorbs ~$0.20 (roughly 4 points) of strategic acquisition dilution implies an ex-deal earnings algorithm closer to low-double-digit/~13–14%. The market traded the 10% headline; the underlying earnings power is stronger.

Analyst Q&A Highlights

What Changed Between the October Comfort and the Lower January Guide

The opening question went straight at the credibility gap: in October management sounded comfortable with consensus revenue growth, and in January it guided below it. The answer pinned the entire half-point delta on the near-term nutrition outlook and reaffirmed that everything else is intact and accelerating.

Q: "On the last call, you seemed comfortable with consensus revenue growth, but you're guiding a little bit lower today. I assume that's related to nutrition. Can you talk about what's changed since the last call?"
— Larry Biegelsen, Wells Fargo

A: "The midpoint here is half a percent lower than what was consensus. But other than that, nothing's really changed… the half-point change on the top line is really the change in the near-term outlook of our nutrition business… A significant majority of the company is either maintaining high-single-digit growth or low-teens growth or accelerating versus 2025."
— Robert Ford, Chairman & CEO

Assessment: The single most important exchange for the rating. Management is isolating the entire guidance disappointment to one fixable segment and reaffirming the rest of the company is on or above algorithm. If that decomposition holds (and the segment-level data supports it) the 10% reaction is an overreaction to a contained problem. This is the basis for the upgrade.

How the 2026 Outlook Was Risk-Adjusted

A follow-up probed management's guidance philosophy, how the outlook was risk-adjusted given the volatility of recent quarters. Ford walked through the build: a large portion of the company sustaining or accelerating high-single-digit growth, a diagnostics acceleration as the ~$1B of 2025 headwind laps, the nutrition transition (one-to-two challenged quarters), and Exact Sciences as an additive vertical.

Q: "As you've thought about putting together the outlook for 2026… how did you think about risk-adjusting the outlook? And… your philosophy as you put the outlook together?"
— David Roman, Goldman Sachs

A: "You've got continued momentum in a large portion of the business… some lapping that's going to be happening [in diagnostics]… and then we've got this [nutrition] transition, which I consider to be pretty short-term… And then… Exact Sciences… another $3 billion-plus business growing 15%."
— Robert Ford, Chairman & CEO

Assessment: The guidance build is coherent and decomposable: durable core + diagnostics lapping + a short nutrition reset + a new growth vertical. The risk concentrates in the nutrition recovery timing; everything else is momentum or lapping. A credible, conservatively-constructed outlook that the market discounted.

CGM Growth Trajectory and the "Market Is Slowing" Debate

A question pressed on whether 2026 CGM growth settles in the low-to-mid-teens and what that implies about market deceleration and Abbott's position. Ford rejected the slowdown framing on an absolute-dollar basis and detailed the penetration runway and expansion vectors.

Q: "You said you expect CGM to continue to track higher at about $1 billion a year. That would put 2026 somewhere in the low-to-mid-teens. Is that the right way to think about CGM growth next year?"
— Robbie Marcus, JPMorgan

A: "I don't consider growing a billion dollars every single year and doing it four years in a row to be slowing down… across all three patient groups… there's so much penetration to be able to have here… we're far away from being in the seventh inning on this one."
— Robert Ford, Chairman & CEO

Assessment: The CGM deceleration is a percentage optic on a $7.5B base, not a demand problem, and the ketone-sensor/SGLT2/CMS-non-insulin vectors are credible re-acceleration paths. Management is not defending a fading asset; it is managing a maturing one with multiple expansion levers. The Libre pillar holds.

Exact Sciences: Close Timing, Dilution, and the MCED Option

A capital-allocation question asked about Exact Sciences close timing and dilution, leverage capacity, and Abbott's stance on M&A versus the spin-offs in vogue across MedTech. Ford confirmed no change to timing (shareholder vote February 20) or the ~$0.20 dilution, ~2.7x post-close leverage, an integration-first focus, and notable enthusiasm for the multi-cancer-early-detection opportunity.

Q: "Any updated thoughts on Exact Sciences deal close timing, dilution… And… how you're thinking about M&A versus divestitures or spin-offs — MedTech right now, spin-off seems to be the flavor of the season?"
— Vijay Kumar, Evercore ISI

A: "There's a shareholder vote on February 20… I'm not changing any assumption regarding timing of close or EPS impact… post-close, our gross debt to EBITDA ratio will be around 2.7 times… greater reimbursement of [MCED] will really make this a very, very large segment… I think your forecast is way undercold."
— Robert Ford, Chairman & CEO

Assessment: The deal is on track and the strategic logic (a 15%-growing cancer-dx vertical with large MCED optionality) is sound. The ~$0.20 dilution is fully in the 2026 guide, so it is a known cost, not a forward surprise; the option value is the unpriced upside. The no-spin-off stance removes a structural overhang some MedTech peers carry.

Electrophysiology Portfolio Completeness vs. Competition

A question asked management to frame the EP portfolio's evolution, past, present, and 6–12 months out, against competition, given the Volt, Tactiflex Duo, and adjacent launches. Ford traced the three-year strategy and argued no competitor matches Abbott's portfolio completeness.

Q: "Can you help us frame the Abbott portfolio in EP… where we are today, where you are six to twelve months from now, and contextualize the portfolio relative to competition… with Volt, Tactiflex Duo…?"
— David Roman, Goldman Sachs

A: "Even without PFA products, we've been able to sustain our double-digit growth rates… The launch of Volt in Europe has gone very well… I don't think there is a company right now that's better positioned in terms of completeness of the portfolio than what we have… I expect that we should grow at least in line with the market… mid to high teens."
— Robert Ford, Chairman & CEO

Assessment: The EP bull case is now fully armed, double-digit growth sustained without PFA, the full PFA toolbox added into an installed mapping base, and an LAA device to round out the portfolio. A mid-to-high-teens 2026 EP growth rate is a meaningful, under-discussed device accelerator.

Nutrition Pricing Confidence and Portfolio Fit

A two-part nutrition question asked what gives management confidence the new prices are the right ones to drive volume, and whether the segment's profitability profile changes how it fits the portfolio. Ford pointed to pre-Thanksgiving pricing tests with quick read-throughs and a profitability profile roughly flat to 2025.

Q: "What gives you confidence that these are the right prices that you're landing at today to drive that volume increase?… presumably nutrition has a different profitability profile — talk about whether it changes your view about how this fits into the entire Abbott portfolio."
— Danielle Antalffy, UBS

A: "We did some pricing work just before Thanksgiving… the early signs are encouraging. But… we gotta keep monitoring this… the profitability… going to be in line with what it was in 2025… shifting some of the focus from marketing and brand to a little bit more price and promotion, at least for these next six months."
— Robert Ford, Chairman & CEO

Assessment: The pricing work is empirical (tested, with fast read-throughs) and the profitability is being held roughly flat, which de-risks the "margin-destroying price war" bear case. The recovery timing (roughly six months) is the key execution variable to watch on the Q1 and Q2 calls.

What They're NOT Saying

1. How deep the nutrition trough goes: Management committed to an H2 recovery but did not quantify the H1 decline or the exit-rate target. "One or two challenged quarters" is directional; the magnitude of the Q1–Q2 drag is left open.
2. The 2026 quarterly cadence beyond Q1: Only Q1 EPS was guided ($1.12–$1.18). The back-half-weighted shape is asserted but not bridged quarter-by-quarter, leaving the acceleration slope to be proven.
3. CGM 2026 growth precision: Ford validated "low-teens" only by not disputing it and reframing to absolute dollars. The exact 2026 CGM growth rate (the most-watched device number) was left soft.
4. Exact Sciences accretion timeline: The ~$0.20 2026 dilution was confirmed, but management gave no timeline to accretion or synergy quantification, "we'll update as we integrate."
5. Whether further price resets are coming in nutrition: The Q4 actions were described, but management did not rule out additional rounds if volume does not respond, which would extend the drag.

Market Reaction

• Pre-print setup: ABT closed at $120.73 on January 21, down 3.6% YTD and roughly flat over the trailing twelve months (+2.5%), having drifted lower from the October print ($129.45) as nutrition and CGM-deceleration worries built. The stock entered the print near the bottom of its $113.48–$140.22 52-week closing range.
• Reaction-day move (January 22, BMO report): Shares gapped down 10.9% at the open ($107.53), traded a $105.78–$114.00 range, and closed at $108.61, down 10.0% ($12.12), a fresh 52-week low.
• Volume: 37.1M shares versus a 6.3M 30-day average, a 5.9x spike, the largest of our coverage and a genuine capitulation-style repositioning.
• Index backdrop: The S&P 500 rose 0.5% on the session, so the entire 10% decline was idiosyncratic.

A 10% drop on a met-EPS quarter is a sentiment event, not a fundamentals event. The tape traded three things: the 2.9% revenue miss, the half-point-light organic guide, and the below-consensus Q1 EPS, all three of which trace to the same fixable nutrition reset. What the reaction ignored: EPS met and grew 12%, full-year EPS hit its double-digit target, gross margin expanded through tariffs, diagnostics inflected, the U.S. Volt approval landed, and Exact Sciences adds a growth vertical.

The setup matters. Abbott entered the print already de-rated (down YTD, near a 52-week low) on the nutrition/CGM worries, so the 10% gap-down took an already-cautious multiple to a multi-year low. That is the opposite of the Q2 air pocket, which came off a YTD high on a priced-for-perfection setup. A 10% capitulation off an already-cautious base, on a fixable one-segment problem, is the classic overdone reaction that creates the asymmetry, and it is why we are upgrading rather than maintaining.

Street Perspective

Debate: Is the Nutrition Problem Transitory or Structural?

Bull view: It is a self-inflicted, fixable price/volume reset on a ~14%-of-revenue segment. Management diagnosed it precisely, tested new pricing empirically (early signs encouraging), is holding profitability flat, and has an 8-plus-product launch cadence. H2 2026 returns to growth; the drag is two-to-three quarters.

Bear view: The CPG dynamic (price-sensitive consumers trading down) is secular, not cyclical, and may require sustained price investment that pressures the segment's economics for longer than "six months." Pediatric share loss (WIC) compounds it. Nutrition could be a multi-year low-growth anchor.

Our take: Bull, with execution risk. The diagnosis and the empirical pricing approach are credible, and management chose decisive short-term pain over a slow decline. The key is whether volume responds by H2; we treat it as a transitory reset and the primary item to verify on the Q1/Q2 calls. Even in a slower-recovery scenario, a 14%-of-revenue segment growing 0–2% does not break a company delivering double-digit EPS.

Debate: Does the De-rating to ~19x Create Asymmetry?

Bull view: At $108.61 and a $5.675 2026 EPS midpoint (which already absorbs ~$0.20 of Exact Sciences dilution), Abbott trades at ~19x forward, a multi-year-low multiple and a clear discount to its history and to medtech peers. For a high-single-digit organic grower with double-digit EPS, an accelerating diagnostics business, 50–70bp annual margin expansion, and a new cancer-dx vertical, the multiple is too low. As nutrition recovers and diagnostics accelerates through 2026, both estimates and the multiple re-rate.

Bear view: ~19x is not screaming cheap for a company that just cut its top-line guide and is leaning on an unproven nutrition recovery and an EPS-dilutive acquisition. The Q1 print will be soft, the nutrition recovery is a show-me, and the multiple could stay compressed until H2 proves the back-half acceleration.

Our take: Bull. ~19x forward for this franchise is the cheapest entry since our initiation, the EPS guide understates the underlying algorithm by ~4 points of deal dilution, and the negatives are concentrated in one fixable segment. The risk/reward has finally become asymmetric, the precise condition we set at initiation for getting constructive.

Debate: Is Exact Sciences a Distraction or a Growth Vertical?

Bull view: Exact Sciences adds a ~$3B, 15%-growing cancer-diagnostics business (Cologuard) with large MCED optionality that the ~$0.20 near-term dilution badly understates. It is a strategically coherent extension of Abbott's diagnostics leadership into oncology and a multi-year growth vertical at an attractive moment in the cancer-screening reimbursement cycle.

Bear view: It is a dilutive deal at the wrong time (near-term EPS drag, integration risk, and leverage to ~2.7x) just as the core needs to prove the nutrition recovery. MCED reimbursement is years away and uncertain.

Our take: Bull, with patience. The dilution is known and in the guide; the growth vertical and MCED option are real and unpriced. Management's integration-first focus is appropriate. We view Exact Sciences as a long-term positive that the market is treating as a near-term negative.

Model & Valuation Framework

Valuation framework: At $108.61 post-print, Abbott trades at ~21.1x the FY2025 actual of $5.15 and ~19.1x the $5.675 2026 EPS midpoint, the lowest forward multiple since our initiation and a clear discount to both its multi-year history and large-cap medtech peers. The base-case target of ~$128 (22.5x the 2026 midpoint) implies ~18% upside; the bull case (~$145, 25.5x) implies ~34%; the bear case (~$100, 17.5x) implies ~8% downside. An up-to-down skew of roughly 2:1 on the base/bear, with a bull case offering 34%, is the asymmetry that was absent at our prior two reviews.

Why upgrade now: at initiation and at Q3 we said we would get constructive on a cheaper entry or hard evidence the diagnostics headwinds were clearing. The Q4 print delivered both (a confirmed diagnostics inflection and a 10% de-rating to a multi-year-low multiple) plus a new growth vertical (Exact Sciences) and a restored margin pillar. The one new negative, nutrition, is a fixable, well-diagnosed, ~14%-of-revenue reset with a visible H2 recovery. The conditions for the upgrade are met.

What would move us back to Hold: the nutrition recovery stalling into H2 2026, a structural CGM deceleration below low-teens, an Exact Sciences integration that proves more dilutive or distracting than guided, or a re-rating back above ~23x without the back-half acceleration materializing. What would move us to Underperform: evidence the nutrition price/volume problem is secular and unfixable, a diagnostics re-deceleration, or a material adverse NEC development.

Thesis Scorecard Post-Earnings

We score this quarter against the standing thesis. The Q3 commitments we set to watch were: the formal 2026 guide (high-single-digit organic + double-digit EPS), a Diagnostics line turning positive, a defended ~57% gross-margin profile, Libre re-accelerating, the 2026 device launch cadence on firm timelines, the NEC federal trend, and any sizable M&A. The scorecard, including two new pillars introduced this quarter:

Overall: The thesis strengthened decisively. Four of five bull pillars are confirmed or strengthened (and a fifth, Exact Sciences, was added), the margin pillar that looked at-risk in Q3 was restored, Bear-1 (diagnostics) is resolving into a 2026 accelerator, and Bear-3 (valuation) flipped from a constraint to a positive on the de-rating. The lone new negative, Bear-5 (nutrition), is a contained, fixable, ~14%-of-revenue reset. The net is a materially better risk/reward at a materially lower price.

Action: Upgrade to Outperform from Hold. The cheaper entry and the diagnostics inflection we set as upgrade conditions both arrived, alongside a new growth vertical and a restored margin pillar. Buy the overdone sell-off.

Bottom Line: The Overdone Sell-Off We Were Waiting For

Rating decision: We upgrade Abbott to Outperform from Hold. Our Hold thesis since July rested on two conditions for getting constructive: a cheaper entry, or hard evidence the diagnostics headwinds were clearing. The Q4 print delivered both at once. The diagnostics inflection is confirmed (Core Lab's third straight quarter of acceleration, the 2025 headwinds lapping into a 2026 tailwind), and a 10% capitulation took the stock to ~19x forward, the lowest multiple of our coverage. On top of that, the margin pillar that looked at-risk in Q3 was restored (gross margin up through tariffs, operating margin +150bp), and a new ~$3B, 15%-growing cancer-diagnostics vertical (Exact Sciences) is inbound.

The market sold a fixable problem. Nutrition's 9% organic decline is real, but it is a self-inflicted, well-diagnosed price/volume reset on a ~14%-of-revenue segment, with empirical pricing tests already showing early signs and a six-month recovery path. The half-point guide cut is entirely nutrition; the 10% EPS guide absorbs ~$0.20 of strategic acquisition dilution, masking an underlying algorithm closer to low-double-digit. Meanwhile EPS met and grew 12%, full-year EPS hit its double-digit target through a brutal headwind year, and the U.S. Volt approval armed the EP bull case. A 10% drop on that mix, off an already-cautious base, is an overreaction.

What we are watching into Q1 2026 (April):